Patents by Inventor Guoliang Zhang

Guoliang Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240166660
    Abstract: Disclosed herein are compounds or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as G12C inhibitors, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 23, 2024
    Inventors: Guoliang ZHANG, Jianzhuang MIAO, Ce WANG, Zhikun NI, Huaguo LI
  • Publication number: 20240166649
    Abstract: Disclosed are a dihydropyrimidine compound, a preparation method therefor and an application thereof. Specifically, disclosed are a dihydropyrimidine compound represented by formula 1? or a pharmaceutically acceptable salt thereof, a composition comprising the compound, and an application of the compound in preparing a drug for treating and preventing hepatitis B virus (HBV) infection related diseases. The disclosed dihydropyrimidine compound can effectively suppress the activity of HBV in HepG2.2.15 cells, and is less toxic to liver cancer cells.
    Type: Application
    Filed: February 8, 2022
    Publication date: May 23, 2024
    Inventors: Guozhi TANG, Dawei MA, Junli CHEN, Mengwei HUANG, Jinliang ZHANG, Guoliang ZHANG
  • Publication number: 20240159423
    Abstract: Disclosed are a method for controlling a variable refrigerant flow (VRF) air conditioner, a VRF air conditioner, and a computer-readable storage medium. The method includes: obtaining a target indoor unit in a warming stage among started indoor units; determining a target superheat degree according to a working condition parameter of the target indoor unit; and adjusting an operating parameter of an electronic expansion valve of the target indoor unit according to the target superheat degree.
    Type: Application
    Filed: January 19, 2024
    Publication date: May 16, 2024
    Applicant: GD MIDEA AIR-CONDITIONING EQUIPMENT CO., LTD.
    Inventors: Kui TAO, Dawei ZHUANG, Zhigang HUANG, Haomin CAO, Guoliang DING, Shunquan LI, Hao ZHANG
  • Patent number: 11966551
    Abstract: Disclosed are a metal mesh touch screen and a method for manufacturing a metal mesh touch screen. The metal mesh touch screen includes the first functional electrode layer, a first adhesive layer, a second functional electrode layer and a second adhesive layer placed sequentially. The first functional electrode layer includes the first metal mesh wiring extending in a first direction and a metal material for preparing the first metal mesh wiring is a metal foil with a first rough surface and a second rough surface. The second functional electrode layer includes a second metal mesh wiring extending in a second direction and a metal material for preparing the second metal mesh wiring is the metal foil with the first rough surface and the second rough surface.
    Type: Grant
    Filed: October 18, 2022
    Date of Patent: April 23, 2024
    Assignee: Micron Optoelectronics Co., Ltd.
    Inventors: Wei Su, Guoliang Zhang, Shourong Hu
  • Publication number: 20240101551
    Abstract: A crystal form and salt form of a bromine domain protein inhibitor represented by formula (I), a preparation method therefor, and a use of the crystal form and salt form in the preparation of a drug for treating diseases mediated by BET protein.
    Type: Application
    Filed: January 19, 2021
    Publication date: March 28, 2024
    Applicants: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., SHOUYAO HOLDINGS (BEIJING) CO., LTD.
    Inventors: Wenwei XU, Zhenliang SHAN, Yingya ZHANG, Guoliang ZHANG, Yun GE, Aiming ZHANG, Xiquan ZHANG
  • Publication number: 20230322788
    Abstract: Disclosed herein are imidazotriazine and pyrrolopyrimidine derivatives or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a G12C inhibitors, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazotriazine and pyrrolopyrimidine derivatives or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as G12C inhibitors.
    Type: Application
    Filed: August 4, 2021
    Publication date: October 12, 2023
    Inventors: Guoliang ZHANG, Jianzhuang MIAO, Ce WANG
  • Publication number: 20230217549
    Abstract: Disclosed are an electrothermal film structure, an electrothermal film heating device and a method for manufacturing an electrothermal film. The electrothermal film structure includes a supporting layer, a meshed conductive circuit layer and a transparent optical layer. The meshed conductive circuit layer provided on the supporting layer includes several micron-level conductive circuits distributed in a mesh, and the transparent optical layer is provided on the meshed conductive circuit layer.
    Type: Application
    Filed: November 18, 2022
    Publication date: July 6, 2023
    Applicant: Micron Optoelectronics Co., Ltd.
    Inventors: Wei SU, Shourong HU, Guoliang ZHANG, Yu SU
  • Publication number: 20230214074
    Abstract: Disclosed are a metal mesh touch screen and a method for manufacturing a metal mesh touch screen. The metal mesh touch screen includes the first functional electrode layer, a first adhesive layer, a second functional electrode layer and a second adhesive layer placed sequentially. The first functional electrode layer includes the first metal mesh wiring extending in a first direction and a metal material for preparing the first metal mesh wiring is a metal foil with a first rough surface and a second rough surface. The second functional electrode layer includes a second metal mesh wiring extending in a second direction and a metal material for preparing the second metal mesh wiring is the metal foil with the first rough surface and the second rough surface.
    Type: Application
    Filed: October 18, 2022
    Publication date: July 6, 2023
    Applicant: Micron Optoelectronics Co., Ltd.
    Inventors: Wei SU, Guoliang ZHANG, Shourong HU
  • Publication number: 20230212192
    Abstract: Disclosed herein are heterocyclic compounds that may be used as STING modulators, the process for synthesis and to the use of such compounds in treatment of various diseases including cancers.
    Type: Application
    Filed: May 27, 2021
    Publication date: July 6, 2023
    Inventors: Jing LI, Sanjia XU, Zhiwei WANG, Guoliang ZHANG, Ce WANG, Jianzhuang MIAO, Lina GU, Gang CHEN, Xiaosong YU
  • Publication number: 20230167117
    Abstract: An imidazo [2,1-f] [1,2,4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof which are used as a TLR7 agonist in the treatment of cancer are provided. Pharmaceutical compositions comprising the imidazo [2,1-f] [1,2,4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof are also provided.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 1, 2023
    Inventors: Guoliang ZHANG, Jianzhuang MIAO, Changyou ZHOU, Gang CHEN
  • Publication number: 20230142738
    Abstract: Disclosed is an electrochromic material. The electrochromic material includes: a low eutectic solvent, and a color-changing material which includes a hydrogen bond donor material and a hydrogen bond acceptor material. The electrochromic material also includes an aerogel.
    Type: Application
    Filed: November 3, 2022
    Publication date: May 11, 2023
    Applicant: Micron Optoelectronics Co., Ltd.
    Inventors: Wei SU, Guoliang ZHANG, Shourong HU
  • Publication number: 20230034083
    Abstract: The present invention relates to a novel polyurethane-based UV-curable composition, comprising a low-crystallinity polyurethane polymer, a multifunctional thiol compound, a multifunctional epoxy resin compound, a photobase generator, and an optional photosensitizer. Adhesive films, adhesive tapes, and bonded members with excellent initial bonding performance, die cutting performance, overlap strength and drop-resistance performance may be obtained by using the polyurethane-based UV-curable composition provided by the present invention.
    Type: Application
    Filed: January 4, 2021
    Publication date: February 2, 2023
    Inventors: Lijing Zhang, Fan Gao, Guoliang Zhang
  • Patent number: 11534431
    Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: December 27, 2022
    Assignee: BEIGENE SWITZERLAND GMBH
    Inventors: Jing Song, Lai Wang, Kang Li, Tong Zhang, Lusong Luo, Min Wei, Zhiyu Tang, Guoliang Zhang, Changyou Zhou
  • Patent number: 11472811
    Abstract: Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an A2A receptor antagonist.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: October 18, 2022
    Assignee: BEIGENE, LTD.
    Inventors: Guoliang Zhang, Changyou Zhou
  • Publication number: 20220289752
    Abstract: Disclosed are an imidazo[2,1-f][1,2,4]triazin-4-amine derivative used as a TLR8 agonist or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same. Further disclosed is a method for treating cancers using the imidazo[2,1-f][1,2,4]triazin-4-amine derivative or the stereoisomer thereof or the pharmaceutically acceptable salt thereof as a TLR8 agonist.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 15, 2022
    Inventors: Guoliang ZHANG, Jianzhuang MIAO, Ce WANG
  • Patent number: 11397147
    Abstract: A test device and method for top-of-the-line corrosion (TLC) of a high-temperature high-pressure wet gas pipeline. The device mainly includes: a metal top cap, a metal reaction cylinder, a first thermometer, a second thermometer, a plastic transparent measuring cylinder, a condensed water collection tube, an atomic spectrometer, a third thermometer, a rubber seal cover, a condensate droplet, a threaded hole, a condensation chamber, a pipeline sample, a temperature measuring hole, and a 30-degree tilt angle. The device and method can effectively simulate TLC of a wet gas pipeline under a high-temperature high-pressure environment. The device and method can test the high-temperature high-pressure TLC of the wet gas pipeline under different temperature differences (between a surface temperature of the pipeline and a gas temperature) and various corrosion media.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: July 26, 2022
    Assignee: SOUTHWEST PETROLEUM UNIVERSITY
    Inventors: Kuanhai Deng, Yuanhua Lin, Yue Yuan, Guoliang Zhang, Zhiping Yin, Dezhi Zeng, Wanying Liu
  • Publication number: 20220119394
    Abstract: Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.
    Type: Application
    Filed: February 6, 2020
    Publication date: April 21, 2022
    Inventors: Guoliang ZHANG, Jianzhuang MIAO, Changyou ZHOU, Gang CHEN, Jing LI
  • Publication number: 20220105033
    Abstract: Disclosed herein is a physically stable solid dispersion comprising Compound 1, i.e., the B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa [b]benzofuran-1 yl)-3-(2, 4, 5-trifluorophenyl) urea and a specific stabilizing polymer, the method for preparing the same, and the uses of the solid dispersion. Also disclosed herein is the crystalline form of Compound 1.
    Type: Application
    Filed: January 23, 2020
    Publication date: April 7, 2022
    Inventors: Guoliang ZHANG, Changyou ZHOU, Huangbin SUN
  • Patent number: 11281313
    Abstract: A mobile device includes a sensing unit configured to determine whether the stylus pen is separated from the mobile device; a communication unit configured to receive a control signal including a first control signal and a second control signal from the stylus pen separated from the mobile device; and a controller configured to operate in a first control mode for performing an operation of an application being executed on the mobile device. The controller performs a first operation of the application in response to the first control signal, and performs a second operation of the application in response to the second control signal.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 22, 2022
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Guoliang Zhang, Rui Zhang, Juexiao Bian
  • Publication number: 20210300936
    Abstract: Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.
    Type: Application
    Filed: July 22, 2019
    Publication date: September 30, 2021
    Inventors: Guoliang ZHANG, Hanzi SUN, Changyou ZHOU